CNS - Cohen & Steers, Inc.
NEW YORK, July 9, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today reported preliminary assets under management of $100.1 billion as of June 30, 2026, an increase of $644 million from assets under management of $99.5 billion at May 31, 2026. The increase was due to market appreciation of $611 million and net inflows of $495 million, partially offset by distributions of $462 million.
NEW YORK, July 8, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) announced that it expects to release second quarter 2026 results after the market closes on Thursday, July 16, 2026. The earnings release and accompanying earnings presentation will be available on the company's website at www.cohenandsteers.com under "Company—Investor Relations—Earnings Archive.
NEW YORK, June 29, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Infrastructure Fund, Inc. (NYSE: UTF) (the "Fund") with information regarding the sources of the distribution to be paid on June 30, 2026 and cumulative distributions paid fiscal year-to-date. In March 2015, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
NEW YORK, June 29, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Total Return Realty Fund, Inc. (NYSE: RFI) (the "Fund") with information regarding the sources of the distribution to be paid on June 30, 2026 and cumulative distributions paid fiscal year-to-date. In December 2011, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
NEW YORK, June 29, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Closed-End Opportunity Fund, Inc. (NYSE: FOF) (the "Fund") with information regarding the sources of the distribution to be paid on June 30, 2026 and cumulative distributions paid fiscal year-to-date. In December 2021, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
NEW YORK, June 29, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers REIT and Preferred and Income Fund, Inc. (NYSE: RNP) (the "Fund") with information regarding the sources of the distribution to be paid on June 30, 2026 and cumulative distributions paid fiscal year-to-date. In December 2017, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
NEW YORK, June 29, 2026 /PRNewswire/ -- This press release provides shareholders of Cohen & Steers Quality Income Realty Fund, Inc. (NYSE: RQI) (the "Fund") with information regarding the sources of the distribution to be paid on June 30, 2026 and cumulative distributions paid fiscal year-to-date. In December 2012, the Fund implemented a managed distribution policy in accordance with exemptive relief issued by the Securities and Exchange Commission.
HOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), announced today that it has signed a national agreement with Elevance Health, Inc. (NYSE: ELV), effective May 1, 2026, covering approximately 45.4 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to 126 million people.
Cohen & Steers, Inc. offers institutional-quality closed-end funds focused on real assets and alternative income, with a recent real estate sell-off creating attractive entry points. Fund sectors include real estate, preferred securities, infrastructure, utilities, and fixed income. C&S's expertise in alternatives, active management, and reliable monthly distributions make their CEFs excellent tools for diversification and steady income.
SAN FRANCISCO and BOSTON, June 24, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system (CNS) disorders, today announced the appointment of Martin Babler and Troy Cox to its Board of Directors following their election at the Company's Annual Meeting of Stockholders on June 23, 2026. Mr. Babler and Mr. Cox succeed Robert Malenka, M.D., Ph.D., and Jim Trenkle, Ph.D., who did not stand for re-election and have concluded their service on the Board. Mr. Babler has been appointed as a member of the Audit Committee, and Mr. Cox has been appointed Chair of the Nominating and Corporate Governance Committee.
CUPERTINO, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, PhD.
Management to update on 2026 mid-year progress, milestones and provide details on its integrated CNS oncology strategy and artificial intelligence plans Management to update on 2026 mid-year progress, milestones and provide details on its integrated CNS oncology strategy and artificial intelligence plans
Partnership delivers real-time DDoS protection and cyber resilience solutions to enterprises, service providers, and critical infrastructure organizations LONDON, June 23, 2026 /PRNewswire/ -- Corero Network Security (AIM: CNS) (OTCQX: DDOSF), leader in real-time DDoS protection and service availability, today announced a strategic partnership with ITcare, a leading provider of technology and managed services solutions. Through this partnership, ITcare will offer Corero's SmartWall ONE™ platform to help organizations defend against increasingly sophisticated Distributed Denial of Service (DDoS) attacks while maintaining business continuity and service availability.
NEW YORK, June 22, 2026 /PRNewswire/ -- The Board of Directors of the Cohen & Steers Closed-End Funds announced today the monthly distributions for July, August and September 2026, as summarized in the charts below: Ticker Fund Name Monthly Dividend FOF Cohen & Steers Closed-End Opportunity Fund, Inc. $0.087 LDP Cohen & Steers Limited Duration Preferred and Income Fund, Inc. $0.131 PSF Cohen & Steers Select Preferred and Income Fund, Inc. $0.126 PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund $0.134 RFI Cohen & Steers Total Return Realty Fund, Inc. $0.080 RLTY Cohen & Steers Real Estate Opportunities and Income Fund $0.110 RNP Cohen & Steers REIT and Preferred and Income Fund, Inc. $0.136 UTF Cohen & Steers Infrastructure Fund, Inc. $0.165 Distributions will be made on the following schedule: Month Ex-Dividend/ Record Date Payable Date July Jul. 14, 2026 Jul. 31, 2026 August Aug. 11, 2026 Aug. 31, 2026 September Sept. 8, 2026 Sept.
CAMBRIDGE, Mass., June 22, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", 3696.HK), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, and SK Biopharmaceuticals, a Korean-based company leads the way in biotech innovation with groundbreaking drug research, development, and commercialization worldwide, announced a research and development collaboration at the BIO 2026 International Convention to discover AI-enabled innovative drug candidates in the neuroimmune area of the central nervous system (CNS).
NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced it is joining patients, caregivers, and advocacy organizations in raising awareness of brain health and the impact of Alzheimer's disease during Alzheimer's & Brain Awareness Month. “Nearly everyone knows brain health is important, but many people aren't sure what steps to take to protect it,” said Wendy Vizek, Senior Vice President, Community Engagement and Field Operations at the Alzheimer's Association.
PHILADELPHIA & BOSTON--(BUSINESS WIRE)--Latus Bio, Inc. (Latus), a biotechnology company engineering gene therapies at scale, today announced the appointment of Bethany Mancilla as Chief Business Officer. Ms. Mancilla brings a breadth of corporate development experience across large and small biotechnology companies, including an extensive history of transactions in gene therapy and central nervous system (CNS) disorders. “Bethany joins Latus at a defining moment as we advance LTS-201 toward th.
NEW YORK, June 15, 2026 /PRNewswire/ -- Cohen & Steers, Inc. (NYSE: CNS) today announced it has completed the conversion the Cohen & Steers Future of Energy Fund (MLOIX) into a new, actively managed exchanged-traded fund (ETF), the Cohen & Steers Future of Energy Active ETF (CSEN). CSEN, listed today on Nasdaq with $189 million in assets, expands Cohen & Steers' actively managed real assets and alternative income ETF platform to more than $1 billion in assets under management[1].
CORAL GABLES, Fla., June 11, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Michael Quirk, PhD, as Senior Advisor – Sepranolone Program. Dr. Quirk's deep expertise in CNS translational science, neuroactive steroid biology, and clinical development will be instrumental in advancing sepranolone, Relmada's GABAA receptor modulator program targeting Prader-Willi Syndrome and other CNS indications.
NEW YORK, June 8, 2026 /PRNewswire/ -- The Board of Directors of the Cohen & Steers Quality Income Realty Fund, Inc. (the "Fund") announced today the monthly distributions for July, August and September 2026, as summarized in the charts below: Ticker Fund Name Monthly Dividend RQI Cohen & Steers Quality Income Realty Fund, Inc. $0.090 The distribution will be made on the following schedule: Month Ex-Dividend/ Record Date Payable Date July Jul. 6, 2026 Jul. 31, 2026 August Aug. 11, 2026 Aug. 31, 2026 September Sept. 8, 2026 Sept.